RNASE1 and hepatocellular carcinoma: Notably, the combination of an ALKi and anti-PD-1 therapy had markedly better antitumor effects than did anti-PD-1 treatment alone without any detectable toxic effects and resulted in the accumulation of T cells with a long-memory phenotype (Figs. 5 and 6), suggesting that ALKi has strong potential for use in combination with immunotherapy in HCC patients with high RNase1 expression.